Strs Ohio Has $16.82 Million Stake in IQVIA Holdings Inc. $IQV

Strs Ohio reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 14.9% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 98,640 shares of the medical research company’s stock after selling 17,206 shares during the quarter. Strs Ohio’s holdings in IQVIA were worth $16,822,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of IQV. Boston Trust Walden Corp bought a new stake in shares of IQVIA during the 1st quarter valued at $443,000. Keybank National Association OH grew its stake in shares of IQVIA by 4.2% during the first quarter. Keybank National Association OH now owns 9,486 shares of the medical research company’s stock worth $1,618,000 after purchasing an additional 383 shares during the period. Heritage Investors Management Corp increased its holdings in IQVIA by 7.1% in the first quarter. Heritage Investors Management Corp now owns 109,388 shares of the medical research company’s stock valued at $18,655,000 after purchasing an additional 7,239 shares during the last quarter. Twin City Private Wealth LLC lifted its stake in IQVIA by 5.6% in the first quarter. Twin City Private Wealth LLC now owns 10,570 shares of the medical research company’s stock valued at $1,803,000 after buying an additional 557 shares during the period. Finally, Fulton Bank N.A. lifted its stake in IQVIA by 8.7% in the first quarter. Fulton Bank N.A. now owns 5,943 shares of the medical research company’s stock valued at $1,014,000 after buying an additional 474 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 0.3%

IQV opened at $206.38 on Friday. The stock has a market capitalization of $34.44 billion, a P/E ratio of 25.57, a P/E/G ratio of 1.78 and a beta of 1.20. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $247.04. The firm’s fifty day simple moving average is $176.95 and its 200 day simple moving average is $189.30.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the company earned $2.70 EPS. The company’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its board has approved a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

Several research firms have recently issued reports on IQV. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. HSBC set a $210.00 target price on shares of IQVIA in a research note on Wednesday, June 3rd. Finally, Evercore reiterated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $222.00.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.